Dr. Jiliang Li, PhD

Position:

· Professor

· Former Chair of Cancer Immunology, Plymouth University & Imperial Cancer Research Fund Fellow

Institution：

Wenzhou Medical University

Education：

· MMed, Sun Yat-Sen University

· Ph.D., University of London

· Postdoctoral Training, University of Oxford

Biography

Dr. Ji-Liang Li received his MMed from Sun Yat-Sen University, Ph.D. from the University of London, and postdoctoral training at the University of Oxford. He has held prestigious positions, including Tenured Scientist at Cancer Research UK and Oxford University, and Tenured Professor and Chair of Cancer Immunology at Plymouth University. Currently, he serves as a Professor at Wenzhou Medical University.

Dr. Li specializes in Molecular Oncology and Translational Medicine, with over 100 publications in renowned journals such as Cancer Cell, Blood, Cell Metabolism, Hepatology, Nature Communications, PNAS, and Cancer Research. His work has been cited over 12,600 times (Google Scholar), with one paper cited over 1,200 times, and 36 papers cited over 100 times. He holds an h-index of 53.

Dr. Li has served on the editorial boards of over 10 international journals and as a reviewer for funding bodies in the UK, Germany, France, the Netherlands, New Zealand, and Singapore. He has established a strong reputation in the field of cancer research.

Research Interests

· Tumor metastasis

· Tumor therapeutic resistance

· Intelligent nanoparticle-based anti-tumor targeted delivery to improve therapeutic efficacy

Selected Publications

1. Li JL, Harris AL. The potential of new tumor endothelium-specific markers for the development of anti-vascular therapy. Cancer Cell, 2007; 11(6):478–482. (Corresponding author)

2. Li JL, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Research, 2011; 71(18):6073–6083. (Corresponding author)

3. Wang S, et al. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology, 2012; 53(6):1932–1942. (Corresponding author)

4. Lyu X, et al. TGFβR2 is a major target of microRNA-93 in nasopharyngeal carcinoma aggressiveness. Molecular Cancer, 2014; 13(1):51. (Corresponding author)

5. Zhang S, et al. Rationally designed enzyme-resistant peptidic assemblies for plasma membrane targeting in cancer treatment. Advanced Healthcare Materials, 2023; 12(21):e2301730. (Corresponding author)

6. Guo Z, et al. Injectable nanocomposite hydrogel with cascade drug release for treatment of uveal melanoma. Journal of Controlled Release, 2024; In press. (Corresponding author)

Contact Information

Email: jlilab1971@163.com